Co-Diagnostics, Inc.

AI-generated fair value estimate for this company.

Method: Adjusted net asset value: $12.71M total stockholders' equity (latest balance sheet) discounted approximately 60% for going-concern/cash-burn risk, divided by 6.25M shares outstanding; no DCF performed because FY2025 revenue collapsed 84% to $622K alongside a $46.9M net loss and the company is not generating sustainable positive cash flow.

Reasoning: With revenue now negligible and recurring losses far exceeding the roughly $3.65M cash balance, a discounted-cash-flow valuation is not meaningful; a book/net-asset value, haircut for continued cash burn and dilution risk ahead of any potential Saudi-facility or Ebola-assay contract wins, is the more defensible approach for this micro-cap.